Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.
The company's operations are categorized into four main segments:
- BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
- BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
- BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
- Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.
Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.
Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.
Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.
Bruker (BRKR) announced major advancements in spatial biology to be unveiled at AGBT 2025, including four key innovations: CosMx Whole Transcriptome Panel (WTX), capable of detecting over 18,000 RNA transcripts at single-cell resolution; expansion of GeoMx protein panel to 1,000-plex capability; launch of PaintScape, a platform for 3D genome visualization; and enhanced CellScape PowerOMX software engine for spatial proteomics.
The WTX assay will begin taking orders in April with summer shipments, while a Mouse version is expected later in 2025. The expanded GeoMx 1K Panel is scheduled for summer release. The company also announced the Sapphire Spatial Program, offering premium services for CosMx SMI users, and extended collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy (SAHA) initiative to map 30 non-diseased organs.
Bruker (BRKR) has announced that its Board of Directors has approved a quarterly cash dividend of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025.
Bruker (BRKR) has announced its senior leadership's participation in four major investor conferences in early 2025. The schedule includes:
- Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York City (February 27, 2:30 PM ET)
- TD Cowen 45th Annual Health Care Conference in Boston (March 5, 11:10 AM ET)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 11, 2:30 PM ET)
- Leerink 2025 Global Healthcare Conference in Miami (March 12, 11:20 AM ET)
All presentations will be accessible via live audio webcasts on Bruker's Investor Relations website. Replay recordings will remain available for at least 30 days after each event in the 'Events & Presentations' section.
Bruker (BRKR) reported Q4 2024 revenues of $979.6 million, up 14.6% year-over-year, with organic revenue growth of 3.9%. The company's Q4 non-GAAP operating margin maintained at 18.1%, with Q4 non-GAAP diluted EPS reaching $0.76, up 8.6% year-over-year.
For full-year 2024, revenues reached $3.37 billion, showing 13.6% growth, with organic revenue up 4.0%. The company's FY 2024 non-GAAP diluted EPS was $2.41, down 6.6% due to strategic acquisitions impact in H1-24.
Looking ahead, Bruker initiated FY 2025 guidance with expected revenue between $3.47-3.54 billion (3-5% growth) and non-GAAP EPS of $2.67-2.72 (11-13% growth). The company completed several strategic acquisitions in 2024, expanding into spatial biology, molecular diagnostics, and lab automation markets.
Bruker (BRKR) has announced its upcoming fourth quarter and fiscal year 2024 financial results release, scheduled for Thursday, February 13, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss results and current business trends.
Investors can access the webcast through Bruker's investor relations website and view an accompanying slide presentation. For telephone access, participants can dial 1-888-437-2685 (U.S. toll-free) or +1-412-317-6702 (international). Pre-registration is available to expedite call entry. A replay will be accessible until March 13, 2025, via 1-877-344-7529 (U.S. toll-free) or +1-412-317-0088 (international) using code 5344184.
Bruker (Nasdaq: BRKR) has launched the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope designed for pharmaceutical and life science research. The device features a patented coherence reduction method for artifact-free infrared laser imaging in both transmission and reflection modes.
The microscope offers ultrafast IR imaging capabilities over large areas with enhanced spatial resolution. Key features include a large field of view, complete automation, and the ability to rapidly determine chemical complexity in biological tissues. The system integrates with Bruker's MALDI Imaging methods for multimodal tissue characterization and includes AI-powered data evaluation.
According to Dr. Guillaume Mabilleau from Centre Hospitalier Universitaire Angers, the microscope's speed and QCL technology represent a significant advancement for clinical research, particularly in bone disease diagnosis and treatment. The system also supports pharmaceutical tablet inspection and particle identification with automated sampling, and includes a Python interface for customization.
Bruker (BRKR) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company will be represented by Frank Laukien (Chairman, President & CEO), Mark Munch (Executive Vice President & President of Bruker Nano Group), and Gerald Herman (Executive Vice President & CFO).
The presentation is scheduled for Monday, January 13th, 2025, at 3:45 PM Pacific Standard Time. Investors can access a live audio webcast through the company's investor relations website at ir.bruker.com. A replay will be available in the 'Events & Presentations' section for 30 days following the event.
Bruker (BRKR) responded to a U.S. District Court ruling in Delaware regarding patent infringement between NanoString and 10x Genomics. The Court upheld a jury's damages award of $31.6 million plus interest for GeoMx Digital Spatial Profiler products. The Court will grant an injunction against GeoMx products in the U.S., with exceptions for consumables sales to existing customers as of November 2023.
The ruling doesn't affect CosMx or nCounter product lines. GeoMx instrument revenue represents less than 0.2% of Bruker's total revenue. The company plans to seek a stay of the injunction and appeal the decision, maintaining that the patents in question are invalid and describe a different method than the GeoMx system.
Bruker (BRKR) faces a permanent injunction in Delaware's U.S. District Court regarding its GeoMx products, following a patent infringement lawsuit by 10x Genomics. The Court will enter the injunction in January 2025, prohibiting Bruker from making, selling, or offering GeoMx Digital Spatial Profiler products in the United States.
The Court affirmed the $31 million damages from the November 2023 jury verdict, plus supplemental damages and interest. Notably, existing GeoMx users who installed instruments before November 18, 2023, can continue purchasing reagents for ongoing research. The jury found that the GeoMx products willfully infringed seven patents licensed to 10x Genomics by Prognosys.
Bruker announces the installation of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, jointly operated by the University of Basel, ETH Zürich, and the University of Zürich. This is Switzerland's second 1.2 GHz NMR, complementing existing equipment including an 800 MHz NMR in Basel.
The new instrument will enhance research capabilities in structural biology and macromolecular analysis, specifically enabling detailed studies of G protein-coupled receptors (GPCRs), intrinsically disordered proteins, and RNA research. The facility will support various applications including protein structure determination, dynamics measurement, ligand binding studies, and protein-protein interaction analysis.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
What does Bruker Corporation specialize in?
How is Bruker Corporation structured?
Where does Bruker generate most of its revenue?
How many employees does Bruker Corporation have?
What industries does Bruker serve?
What recent advancements has Bruker made?
What is BSI BioSpin known for?
Why are Bruker's technologies important in industrial production?
What is the BEST segment of Bruker Corporation?
How does Bruker Corporation contribute to scientific research?
